SCHEMBL5534028

SCHEMBL5534028

C=Cc1ccc(NC(=O)c2cc(Cl)ccc2N(C=O)c2ccc(C=NN(C)Cc3ccco3)cc2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.37
MEN1 O00255 5/20 0.37
KMT2A Q03164 5/20 0.37
MAPT P10636 5/20 0.37
HPGD P15428 4/20 0.37
KDM4E B2RXH2 3/20 0.37
HSD17B10 Q99714 2/20 0.37
THRB P10828 1/20 0.36
POLB P06746 3/20 0.35
NPC1 O15118 3/20 0.35
AHR P35869 1/20 0.35
HTT P42858 4/20 0.35
LMNA P02545 3/20 0.35
GAA P10253 2/20 0.34
NPSR1 Q6W5P4 1/20 0.34
NR3C1 P04150 1/20 0.33
TP53 P04637 3/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
RAB9A P51151 3/20 0.33
MAPK1 P28482 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5553904 0.90 KDM4E (0.38) ALDH1A1HPGDKDM4EHSD17B10HTT
SCHEMBL5529583 0.86 ALDH1A1 (0.43) ALDH1A1MEN1KMT2AMAPTHPGD
SCHEMBL5534188 0.85 NPC1 (0.39) ALDH1A1MEN1KMT2AMAPTHPGD
SCHEMBL5540990 0.85 ALDH1A1 (0.39) ALDH1A1MAPTHPGDKDM4EPOLB
SCHEMBL6841560 0.84 POLB (0.42) ALDH1A1MEN1KMT2AMAPTKDM4E
SCHEMBL5532923 0.83 NPC1 (0.38) ALDH1A1MEN1KMT2AMAPTHPGD
SCHEMBL5527895 0.83 NPC1 (0.42) ALDH1A1MEN1KMT2AMAPTHPGD
SCHEMBL5536642 0.76 F10 (0.41)
SCHEMBL5538464 0.75 F10 (0.42) ALDH1A1MEN1KMT2AMAPTKDM4E
SCHEMBL5549858 0.75 F10 (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1373194-A1 BENZAMIDE INHIBITORS OF FACTOR Xa Millennium Pharmaceuticals, Inc. (US) 2004-01-02 EP claimed
US-20030069250-A1 Benzamide inhibitors of factor Xa MILLENNIUM PHARMACEUTICALS, INC. 2003-04-10 US claimed
WO-2002079145-A1 BENZAMIDE INHIBITORS OF FACTOR Xa MILLENNIUM PHARMACEUTICALS, INC. (US) 2002-10-10 WO claimed
US-7312235-B2 Benzamide inhibitors of factor Xa MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-12-25 US disclosed
EP-1373194-B1 BENZAMIDE INHIBITORS OF FACTOR Xa MILLENNIUM PHARM INC (US) 2007-08-01 EP disclosed
EP-1373194-A1 BENZAMIDE INHIBITORS OF FACTOR Xa Millennium Pharmaceuticals, Inc. (US) 2004-01-02 EP disclosed
US-20030069250-A1 Benzamide inhibitors of factor Xa MILLENNIUM PHARMACEUTICALS, INC. 2003-04-10 US disclosed
WO-2002079145-A1 BENZAMIDE INHIBITORS OF FACTOR Xa MILLENNIUM PHARMACEUTICALS, INC. (US) 2002-10-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069250-A1 Benzamide inhibitors of factor Xa SERPINC1, TFPI, F12 ALDH1A1 2162/4885MEN1 2370/4885KMT2A 2096/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.